What Has Been The Evolution of the Aurora Kinase B Market in Recent Years?
The aurora kinase b market has seen considerable growth due to a variety of factors.
• The market size for aurora kinase b has noticeably expanded over the past few years. Its projection indicates an increase from $1.14 billion in 2024, escalating to $1.27 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%.
This considerable growth during the historic period can be credited to the heightened demand for cancer therapies aim at specific targets, a global increase in cancer cases, the rising investment in precision medicine, an increase in clinical trials, and the rise in government funding for cancer research.
What Are the Future Growth Projections for the Aurora Kinase B Market?
The aurora kinase b market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of aurora kinase b is anticipated to experience swift expansion. It is projected to reach $1.99 billion in 2029, with an 11.8% compound annual growth rate (CAGR).
This growth during the forecasted period can be ascribed to the increasing investments in unique cancer therapies, escalating occurrence of drug-resistant cancers, expanding research and development, growing need for combination treatments, and the rising prevalence of solid tumors. The major trends during this period will encompass advancements in technology, precision medication, innovative treatments, data analyses, and fresh therapies.
What Are the Critical Driver Fuelling The Aurora Kinase B Market's Growth?
The augmentation of cancer cases is anticipated to stimulate the expansion of the aurora kinase B market in the future. Cancer is identified as a compilation of diseases denoted by the unregulated proliferation and dissemination of irregular cells which can infiltrate nearby tissues and spread to diverse body parts. The surge in cancer cases can be attributed to elements such as an older population demographic, alterations in lifestyle, exposure to environmental elements, and bettered discovery and diagnostic methods. The aurora kinase B is pivotal in mitosis and the excessive expression of it is correlated with chromosomal instability and the advancement of cancer. Its role in facilitating the division of tumor cells makes it a common target in cancer therapies. For example, in February 2024, as per the World Health Organization, a Switzerland-based intergovernmental agency, approximately 20 million novel cancer cases were documented in 2022, along with a death toll of 9.7 million. New cancer cases are predicted to surpass 35 million by 2050, signifying a 77% upsurge from 2022. Hence, this escalating prevalence of cancer is fuelling the expansion of the aurora kinase B market.
What Are The Major Segments Within The Global Aurora Kinase B Market?
The aurora kinase b market covered in this report is segmented –
1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology
Pre-Book The Aurora Kinase B Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Aurora Kinase B Market?
Leading companies in the aurora kinase B market are working on the creation of cutting-edge products, such as aurora kinase inhibitors, which are specifically designed to interfere with essential cell division processes. These drugs work by stopping the functioning of Aurora kinases, crucial to cell division, thus hindering cancer cell propagation and possibly decreasing tumor growth. For example, in June 2023, UK-based biotech firm Ellipses Pharma secured approval from the U.S. Food and Drug Administration (FDA) for its EP0042, a combined FLT-3 and Aurora kinase inhibitor. EP0042 is under development as a treatment for acute myeloid leukemia (AML) and is an inhibitor that targets both FLT3 and Aurora kinase. This treatment strategy is uniquely designed for AML patients who have developed resistance to FLT3 inhibitors. Studies have shown that dual inhibition of FLT3 and Aurora kinase can surpass acquired resistance to selective FLT3 inhibition in vitro and in vivo.
Who Are the Key Players In The Aurora Kinase B Market?
Major companies operating in the aurora kinase B market are:
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Astellas Pharma Inc.
• Promega Corporation
• Rigel Pharmaceuticals Inc.
• Tocris Bioscience
• BPS Bioscience Inc.
• Advenchen Laboratories LLC
• Shenzhen Chipscreen Biosciences Co. Ltd.
• Cyclacel Pharmaceuticals Inc.
• Sareum Holdings plc
What Is The Most Dominant Region In The Aurora Kinase B Market?
North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
